Abstract
Vindesine, a vinblastine derivative, began clinical trial in 1975. It has an antitumor spectrum in animals similar to that of vincristine, but with less neurotoxicity. Phase I trials of vindesine at Memorial Sloan-Kettering Cancer Center explored both a weekly and a daily x 5 dose schedule. A dose of 1.3 mg/m 2/day x 5-7 days every 3 weeks was well-tolerated. There were 2 measurable remissions in 6 heavily pretreated patients with testicular cancer. A phase II trial of vindesine in patients with germ-cell tumors who had failed to respond to conventional chemotherapy was begun in January 1977 and this is a report of the results.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1399-1401 |
| Number of pages | 3 |
| Journal | Cancer Treatment Reports |
| Volume | 63 |
| Issue number | 8 |
| State | Published - 1979 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
